Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score
| Autor: | Javier Domínguez-Ortega, Iñigo Ojanguren, Gregorio Soto, José María Vega Chicote, Antonio Parra Arrondo, Miguel Perpiñá, Carolina Cisneros, Isabel Urrutia, Juan Luis García-Rivero, Eva Martínez-Moragón, Carlos Almonacid, Valentina Gutiérrez Vall De Cabrës, Irina Bobolea, Antolín López Viña, Marina Blanco, Dario Antolin, Astrid Crespo, Alfons Torrego, Joaquín Sastre Domínguez, Paloma Campo Mozo, Victoria García Gallardo, Vicente Plaza, Mar Mosteiro, Ismael García Moguel, Ignacio Dávila, Carlos Colás, Aythamy Henrquez Santana, Luis Pérez de Llano, Alicia Habernau Mena, Francisco Álvarez, Juan Carlos Miralles, Remedios Cardenas Contreras, Borja G. Cosío, Manuel Jorge Rial Prado, César Picado, Loreto Carmona, José María Olaguibel Rivera, Xavi Muñoz, Santiago Quirce Gancedo, Pilar Barranco Sanz, José Ramón Serrano, Ignacio Antepara Ercoreca, Julio Delgado Romero, Cristian Domingo, María Jesús García de Yébenes |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Potentially all pairwise rankings of all possible alternatives business.industry Maintenance dose medicine.drug_class Intraclass correlation Minimal clinically important difference Context (language use) medicine.disease 03 medical and health sciences 0302 clinical medicine 030228 respiratory system Internal medicine medicine Immunology and Allergy Corticosteroid 030212 general & internal medicine business Face validity Asthma |
| Zdroj: | The Journal of Allergy and Clinical Immunology: In Practice. 9:2725-2731 |
| ISSN: | 2213-2198 |
| DOI: | 10.1016/j.jaip.2021.01.033 |
| Popis: | Background There is a lack of tools to quantify the response to monoclonal antibodies (mAbs) holistically in severe uncontrolled asthma patients. Objective To develop a valid score to assist specialists in this clinical context. Methods The score was developed in four subsequent phases: (1) elaboration of the theoretical model of the construct intended to be measured (response to mAbs); (2) definition and selection of items and measurement instruments by Delphi survey; (3) weight assignment of the selected items by multicriteria decision analysis using the Potentially All Pairwise RanKings of All Possible Alternatives methodology using the 1000minds software; and (4) face validity assessment of the obtained score. Results Four core items, with different levels of response for each, were selected: severe exacerbations, oral corticosteroid use, symptoms (evaluated by Asthma Control Test), and bronchial obstruction (assessed by FEV1 percent predicted). Severe exacerbations and oral corticosteroid maintenance dose were weighted most heavily (38% each), followed by symptoms (13%) and FEV1 (11%). Higher scores in the weighted system indicate a better response and the range of responses runs from 0 (worsening) to 100 (best possible response). Face validity was high (intraclass correlation coefficient of 0.86). Conclusions The FEV1, exacerbations, oral corticosteroids, symptoms score allows clinicians to quantify response in severe uncontrolled asthma patients who are being treated with mAbs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|